Woodard T L, Burghen G A, Kitabchi A E, Wilimas J A
J Clin Endocrinol Metab. 1981 Nov;53(5):905-8. doi: 10.1210/jcem-53-5-905.
Because of a suspected association between the drug oxymetholone and abnormal glucose metabolism, we determined immunoreactive insulin (IRI) and plasma glucose during oral glucose tolerance testing in seven patients with aplastic anemia, six of whom received oxymetholone therapy. All patients receiving oxymetholone therapy had abnormal glucose and/or IRI values. This finding was independent of GH, cortisol, and glucagon. In one patient, glucose and IRI levels were normal before oxymetholone but became abnormally elevated after the use of this drug. Furthermore, normal glucose and IRI values were present in the single patient not receiving oxymetholone. Thus, a positive relationship was demonstrated between oxymetholone administration and the presence of glucose intolerance and insulin resistance.
由于怀疑羟甲烯龙药物与异常葡萄糖代谢之间存在关联,我们在七名再生障碍性贫血患者的口服葡萄糖耐量试验期间测定了免疫反应性胰岛素(IRI)和血糖,其中六名患者接受了羟甲烯龙治疗。所有接受羟甲烯龙治疗的患者均有异常的血糖和/或IRI值。这一发现与生长激素、皮质醇和胰高血糖素无关。在一名患者中,服用羟甲烯龙前血糖和IRI水平正常,但使用该药物后异常升高。此外,未接受羟甲烯龙治疗的唯一患者血糖和IRI值正常。因此,证实了羟甲烯龙给药与葡萄糖不耐受和胰岛素抵抗之间存在正相关关系。